Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895704 | 0.99 | KDM1A (0.45) | KDM1APTPN1PTPN2PTGER1SLC6A4 | |
| Potassium SCHEMBL2895709 | 0.99 | KDM1A (0.45) | KDM1APTPN1PTPN2PTGER1SLC6A4 | |
| SCHEMBL25325323 | 0.88 | PTPN1 (0.47) | KDM1APTPN1PTPN2 | |
| SCHEMBL2896992 | 0.87 | PTPN1 (0.43) | PTPN1PTPN2FFAR1MRGPRX4MAPK14 | |
| SCHEMBL2895984 | 0.87 | PTPN1 (0.45) | PTPN1PTPN2SLC6A4FFAR1MRGPRX4 | |
| SCHEMBL646553 | 0.87 | PTPN1 (0.43) | KDM1APTPN1PTPN2PTGER1SLC6A4 | |
| SCHEMBL2895219 | 0.86 | PTPN1 (0.43) | PTPN1PTPN2FFAR1MRGPRX4 | |
| Potassium SCHEMBL2895227 | 0.86 | PTPN1 (0.43) | PTPN1PTPN2FFAR1MRGPRX4 | |
| SCHEMBL2905556 | 0.85 | PTPN1 (0.43) | PTPN1PTPN2FFAR1MAPK14 | |
| SCHEMBL31285190 | 0.85 | PTPN1 (0.41) | PTPN1PTPN2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313554-A1 | PTPN2 INHIBITORS | MONDEGO BIO, LDA. (PT) | 2025-10-09 | — | — | US | disclosed |
| EP-4522594-A1 | PTPN2 INHIBITORS | Ness Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119522216-A | PTPN2 inhibitors | 尼斯治疗公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2023220572-A1 | PTPN2 INHIBITORS | NESS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4211122-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022261145-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | NESS THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3938038-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020186199-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | KDM1A 1844/4885PTPN1 1/4885PTPN2 2/4885 |
| US-20250313554-A1 | PTPN2 INHIBITORS | PTPN2, PTPN1, PTPRJ | KDM1A 1545/4885PTPN1 2/4885PTPN2 1/4885 |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | KDM1A 2605/4885PTPN1 11/4885PTPN2 5/4885 |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | KDM1A 1844/4885PTPN1 1/4885PTPN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.